Industry News

U.S. FDA Grants Priority Review to Simeprevir TMC435 for Combination Treatment of Genotype 1 Chronic Hepatitis C Janssen Research & Development, Llc
Upsher-Smith Successfully Completes Phase III Study Of USL255 (Extended-Release Topiramate) For Adjunctive Treatment Of Epilepsy In Patients With Refractory Partial-Onset Seizures Global Study Advances Upsher-Smith's CNS Pipeline
Boehringer Ingelheim responds to FDA warning letter
Svelte Drug-Eluting Stent Utilizing New Class of Bioabsorbable Drug Coating Attains 0% Clinically-Driven Events Through 12-Months in First-In-Man Study
J&J's Janssen Poised to Continue Driving Growth, Outlines 10+ Potential New Product Filings by 2017
Small in Stature: New Technology from Baxter Makes an Impact
GlaxoSmithKline awarded up to $200 million by U.S. government to develop new antibiotics
Sandoz launches first generic version of ATACAND
Pfizer Terminates Phase 3 Study of Inotuzumab Ozogamicin in Relapsed or Refractory Aggressive Non-Hodgkin Lymphoma (NHL) Due to Futility
Forest Labs CEO Howard Solomon to retire
Par Pharmaceutical Begins Shipment of Generic Atacand
BD Issues 2012 Sustainability Report A Shared Value Approach
CareFusion Foundation Announces Clinical Excellence Grant Recipients More than $500,000 awarded to help hospitals improve infection prevention practices
Mayo Clinic Forms Joint Venture with Cancer Genetics
Par Pharmaceutical Begins Shipment of Generic Atacand®
Upsher-Smith Successfully Completes Phase III Study Of USL255 (Extended-Release Topiramate) For Adjunctive Treatment Of Epilepsy In Patients With Refractory Partial-Onset Seizures Global Study Advances Upsher-Smith's CNS Pipeline
UPDATE: Pfizer to Split Off Remaining Interest in Zoetis
BD Issues 2012 Sustainability Report A Shared Value Approach
CareFusion Foundation Announces Clinical Excellence Grant Recipients More than $500,000 awarded to help hospitals improve infection prevention practices
Bayer to acquire Steigerwald Arzneimittelwerk GmbH
Bayer to acquire Steigerwald Arzneimittelwerk GmbH
NAFDAC to Prosecute Owners of Fake Drugs' Warehouses
NAFDAC to Prosecute Owners of Fake Drugs' Warehouses
Actavis to Acquire Warner Chilcott to Create Premier $11 Billion Revenue Global Specialty Pharmaceutical Company - Top 3 U.S. ~$3.0 Billion Revenue Specialty Brand Business -- Expands Portfolio and Pipeline in Core Areas of Women's Health and
Actavis to Acquire Warner Chilcott to Create Premier $11 Billion Revenue Global Specialty Pharmaceutical Company - Top 3 U.S. ~$3.0 Billion Revenue Specialty Brand Business -- Expands Portfolio and Pipeline in Core Areas of Women's Health and